Amgen announced data from the final analysis of the Phase 2 OCEAN-DOSE study of olpasiran, a small interfering RNA during the Late-Breaking Science Session at the European Society of Cardiology Annual Meeting being held in Amsterdam.
Amgen announced data from the final analysis of the Phase 2 OCEAN-DOSE study of olpasiran, a small interfering RNA during the Late-Breaking Science Session at the European Society of Cardiology Annual Meeting being held in Amsterdam.